Ryan Hudson
Vice President, Discovery Chemistry
Professional Overview
Ryan Hudson is an accomplished pharmaceutical executive with over 15 years of experience in discovery chemistry and drug development. As the Vice President of Discovery Chemistry at Neumora, he leads a team of highly skilled scientists focused on the research and development of novel therapies for central nervous system (CNS) disorders.
Experience Summary
Current Role
In his current position at Neumora, Mr. Hudson is responsible for overseeing all aspects of the discovery chemistry program, from initial target identification to lead optimization. He has played a pivotal role in advancing several promising drug candidates through the pipeline, leveraging his deep expertise in medicinal chemistry and his ability to drive cross-functional collaboration.
Career Progression
Prior to joining Neumora, Mr. Hudson held progressive leadership roles in the biotechnology industry. As the Vice President and Head of Chemistry at UNITY Biotechnology, he led a team of scientists focused on the development of senolytic therapies to treat age-related diseases. Earlier in his career, he served as an Associate Director of Medicinal Chemistry at Corvus Pharmaceuticals, where he contributed to the discovery and optimization of novel immunotherapies. He also spent a decade at Theravance, where he made significant contributions to the company's small molecule drug discovery efforts.
Academic Background
Mr. Hudson holds a Bachelor of Science degree in Chemistry from the University of California, Berkeley, and a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology. During his doctoral research, he developed expertise in synthetic organic chemistry and its application to drug discovery.
Areas of Expertise
- Medicinal chemistry and small molecule drug discovery
- Target identification and lead optimization
- CNS drug development
- Cross-functional team leadership and collaboration
- Strategic planning and project management
Professional Impact
Throughout his career, Mr. Hudson has made notable contributions to the development of several clinical-stage drug candidates, including a first-in-class Alzheimer's disease therapy currently in Phase III trials. His work has been recognized through multiple publications in peer-reviewed journals and presentations at industry conferences.
Conclusion
With his deep scientific expertise, proven track record of success, and strong leadership abilities, Ryan Hudson is well-positioned to continue driving innovation and advancing Neumora's mission to develop transformative therapies for patients with CNS disorders.
